Transferangebote:

 

Alle Institute dieser Sektion

Aß-directed peptides

Peptides for the Diagnosis and Therapy of Alzheimer’s Disease

Kurzbeschreibung

Challenge
Current scientific research in the field of Alzheimer’s Disease (AD) focuses on the identification of Abeta plaque precursor fibrils, their occurrence in diseased brains and amyloid plaques, and their role in the pathogenic processes. A strong need is felt for therapeutics, but also for means for detection of amyloid plaques during disease stages without or only minor onset of AD symptoms. Such diagnostic tools are also of importance for monitoring the disease progression and therapy effects in a non-invasive way.
 
Technology
The technology relates to synthetic D-Peptides, specific for Ab42 amyloid plaques and highly affine with an in vitro KD in the submicromolar range. Evidence for in vivo binding was given by histological analysis of transgenic mice brain tissues. Two D-peptides D1 and D3 were functionally tested in AD transgenic mice models.
Upon intracranial administration, in vivo plaque specificity of D1 could be confirmed, without brain inflammation or uptake by astrocytes or microglia even after long-term infusion and in good correlation to results from cellular cytotoxicity assays. D1 may therefore be suitable for measuring plaque load in the living brain for early onset of the disease, and monitoring of plaque load during disease progression and treatment.
D3 reduces the amyloid plaque load in transgenic mice after a 4 weeks intracranical infusion. Upon oral administration the cognitive behaviour of treated mice improved, making D3 to a promising candidate molecule for therapeutic purposes.
Current preliminary data indicate the passage of the blood brain barrier for both peptides.
 
Further Reading
Funke et al., Curr Pharm Des 2012, in press
Funke et al., ACS Chem. Neurosci. 2010. 1(9), 639-648
Van Groen et al., ChemBioChem 2009, 4, 276-282
Van Groen et al., ChemBioChem 2008, 3, 1848-1852
Wiesehan et al., ChemBioChem 2003, 4, 748-753

Technologie

Entwicklungsstand

A European Patent is granted.

Vorteile/Nutzen

The peptide D3 reduces the amyloid plaque load in transgenic mice after a 4 weeks intracranical infusion. Upon oral administration the cognitive behaviour of treated mice improved, making D3 to a promising candidate molecule for therapeutic purposes.

Publikationsnummer

EP 1379546

Ansprechpartner Patentverwertung

Dr. Sabina Heim
Technology Manager
Ascenion GmbH

T: +49 (0)531 618120-91
F: +49 (0)531 618120-98
heim@ascenion.de

Angebot ist interessant für

Commercial Opportunity: In-licensing and collaboration opportunity

 

Anschrift

  • Beutenbergstraße 11
  • 07745 Jena

Ansprechpartner

 
interner Link: Start Sprungmarke externer Link: http://www.bmwi.de/, öffnet in einem neuen Fenster externer Link: http://www.signo-deutschland.de/hochschulen, öffnet in einem neuen Fenster